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RANDOMIZED CONTROLLED TRIALLaparoscopic Sleeve Gastrectomy Versus Roux-Y-Gastric Bypass
for Morbid Obesity—3-Year Outcomes of the Prospective
Randomized Swiss Multicenter Bypass Or Sleeve StudyBOSS)(SM-Ralph Peterli, MD, Bettina Karin Wo¨lnerhanssen, MD,yz Diana Vetter, MD,§ Philipp Nett, MD,
Markus Gass, MD, Yves Borbe´ly, MD, Thomas Peters, MD,jj Marc Schiesser, MD, Bernd Schultes, MD,yy
Christoph Beglinger, MD,y Juergen Drewe, MD, MSc,zz and Marco Bueter, MD, PhD§Objective: Laparoscopic sleeve gastrectomy (LSG) is performed almost as
often in Europe as laparoscopic Roux-Y-Gastric Bypass (LRYGB). We present
the 3-year interim results of the 5-year prospective, randomized trial comparing
the 2 procedures (Swiss Multicentre Bypass Or Sleeve Study; SM-BOSS).
Methods: Initially, 217 patients (LSG, n ¼ 107; LRYGB, n ¼ 110) were
randomized to receive either LSG or LRYGB at 4 bariatric centers in
Switzerland. Mean body mass index of all patients was 44 11 kg/m2, mean
age was 43 5.3 years, and 72% of patients were female. Minimal follow-up
was 3 years with a rate of 97%. Both groups were compared for weight loss,
comorbidities, quality of life, and complications.
Results: Excessive body mass index loss was similar between LSG and
LRYGB at each time point (1 year: 72.3 21.9% vs. 76.6 20.9%, P ¼
0.139; 2 years: 74.7 29.8% vs. 77.7 30%, P ¼ 0.513; 3 years:
70.9 23.8% vs. 73.8 23.3%, P ¼ 0.316). At this interim 3-year time
point, comorbidities were significantly reduced and comparable after both
procedures except for gastro-esophageal reflux disease and dyslipidemia,
which were more successfully treated by LRYGB. Quality of life increased
significantly in both groups after 1, 2, and 3 years postsurgery. There was no
statistically significant difference in number of complications treated by
reoperation (LSG, n ¼ 9; LRYGB, n ¼ 16, P ¼ 0.15) or number of
complications treated conservatively.
Conclusions: In this trial, LSG and LRYGB are equally efficient regarding
weight loss, quality of life, and complications up to 3 years postsurgery.
Improvement of comorbidities is similar except for gastro-esophageal reflux
disease and dyslipidemia that appear to be more successfully treated byLRYGB.
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T he last 30 years have brought a dramatic increase in obesityworldwide.1 Currently, bariatric surgery is the only efficient
treatment option leading to sustainable weight loss and reduction
in comorbidities in morbidly obese patients.2 Therefore, there has
been a continuously rapid growth in the number of bariatric inter-
ventions.3 There are a multitude of different surgical procedures and
each intervention has its own profile of advantages and disadvan-
tages. Up to now, there is no clear consensus on which procedure
should be applied in each respective case. Currently, laparoscopic
gastric bypass (LRYGB) is regarded as the gold standard treatment,
but this procedure is challenged by other procedures such as sleeve
gastrectomy or single anastomosis gastric bypass, always expecting
to find even more efficient but equally or even safer procedures.3
Laparoscopic gastric banding temporarily gained popularity due to
its easy application and the reversibility of this procedure. In the
meantime, an increasing number of trials have shown the consider-
able drawbacks of this procedure (low grade of efficiency combined
with poor quality of life and a high reoperation rate), and this
intervention has more or less been abandoned in Europe.3–5
In LRYGB, the stomach is divided into a small upper pouch
and a larger gastric remnant, and the small intestine is rearranged in a
way that, in the final state, from the small gastric pouch the ingested
food enters the jejunum (alimentary limb) directly and is not exposed
to digestive liquids until it reaches the entero-enterostomy (‘‘Y
intersection’’) at about 150 cm, where the biliopancreatic limb
(excluded gastric remnant plus duodenum, and approximately
50 cm of proximal jejunum) is reconnected and the remaining small
intestine forms the common channel. This rearrangement of the small
intestine bears the risk of a typical complication ‘‘the internal
hernia,’’ where the small bowel becomes trapped and obstructed;
a condition that usually requires reoperation and can potentially have
fatal consequences if not recognized and treated adequately. Internal
hernia can occur many years after the original operation and is found
in 1% to 11% of LRYGB patients.6
In laparoscopic sleeve gastrectomy (LSG) a large portion of
the stomach along the greater curvature is removed resulting in a
‘‘sleeve’’-like tube; however, no rearrangement of the small bowel is
performed. Hence, this particular complication is not found after
LSG (a clear argument in its favor); however, efficiency in remission
of comorbidities is still a matter of debate.
Other potential advantages of LSG are that the procedure
seems technically easier than LRYGB, shows lower early morbidity
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TABLE 1. Baseline Demographic Data
LSG LRYGB P Value
Age (yrs; meanSD) 43.0 11.1 42.1 11.2 NS
Female (n (%) 77 (72) 79 (72) NS
Weight (kg; meanSD) 123.5 19.4 124.8 19.8 NS
BMI (kg/m2; meanSD) 43.6 5.3 44.2 5.3 NS
QoL (GIQLI score; meanSD) 99.0 20.5 98.8 17.4 NS
Hypertension (%) 63 59 NS
Diabetes (%) 24 26 NS
Dyslipidemia (%) 67 51 NS
OSAS (%) 48 42 NS
GERD (%) 44 46 NS
Back/joint pain (Arthralgia) (%) 61 68 NS
Hyperuricemia (%) 15 10 NS
Depression (%) 20 11 NS
GERD indicates gastro-esophageal reflux disease; GIQLI, Gastrointestinal Quality
of Life Index; NS, nonsignificant; OSAS, obstructive sleep apnea syndrome.
Annals of Surgery  Volume 265, Number 3, March 2017 LSG Vs. LRYGB Similar 3-Year Outcomeand lower prevalence of dumping symptoms. However, the LSG
procedure is irreversible as the larger portion of the stomach is
removed, whereas LRYGB is (at least to some extent) reversible.
Furthermore, long-term outcome results after LSG are still scarce. A
few randomized-controlled studies have compared outcome of
LRYGB versus LSG, unfortunately with only a small number of
patients or short follow-up.7–12 Up to now there is no clear evidence
showing that 1 of these 2 procedures is superior to the other in long-
term outcome.
The Swiss Multicentre Bypass Or Sleeve Study (SM-BOSS) is
the first, prospective randomized trial comparing outcomes of LSG to
LRYGB with an adequate number of patients and a nearly complete
follow-up rate of 97% after 3 years.
METHODS
Study Design
The rationale, design, and methods of this study have been
reported previously.13 The study protocol was reviewed and approved
by the local ethical committees of each participating hospital and
conducted in accordance with the principles of the Declaration of
Helsinki and the trial was registered at the clinical trials registry of
the National Institutes of Health (NCT 00356213). To summarize, the
trial was a 2-group, randomized, controlled, multicenter study
involving 217 morbidly obese patients, in which the outcomes of
LSG were compared to those of LRYGB. Four bariatric centers in
Switzerland participated in this trial, each with at least 10 years of
bariatric experience and at least 200 bariatric procedures performed
per year. Only surgeons with a personal experience of at least 400
bariatric interventions participated in this trial. On a regular basis
research meetings were held, to enhance adherence to the protocol
and guarantee high data quality.
Patients were assigned to either the LSG or LRYGB group,
using a computer-based randomization with sealed envelopes. Eligi-
bility criteria included an age of 18 to 65 years, a body mass index
(BMI, the weight in kilograms divided by the square of the height in
meters) >40 or >35 kg/m2 with the presence of at least 1 comor-
bidity, and failure of conservative treatment over 2 years. Exclusion
criteria were: symptomatic gastro-esophageal reflux disease (GERD)
despite medication (severe GERD), large hiatal hernia (para-esoph-
ageal hernia or axial hernia >4 cm), expected dense adhesions at the
TABLE 2. Improvement in Comorbidities
OP Type (%: Preoperative
Prevalence of Comorbidity) Remission (%)
Hypertension LSG (63%) 65.2
LRYGB (59%) 71.2
Dyslipidemia LSG (67%) 43.8
LRYGB (51%) 71.7
T2DM LSG (24%) 60.0
LRYGB (26%) 77.0
OSAS LSG (48%) 90.2
LRYGB (42%) 82.2
Back/joint pain LSG (61%) 44.2
LRYGB (68%) 42.5
GERDy LSG (44%) 61.0
LRYGB (46%) 77.6
Hyperuricemia LSG (15%) 81.8
LRYGB (10%) 100
Depression LSG (20%) 26.7
LRYGB (11%) 33.4
Comparing improvement of comorbidities between the 2 groups, the only statistically
preexisting GERD (y), where LRYGB was superior to LSG 3 years after surgery. In brakes
 2016 The Author(s). Published by Wolters Kluwer Health, Inc.level of the small bowel, the need for endoscopic follow-up of the
duodenum, and patients with inflammatory bowel disease. All
patients gave written informed consent.
This investigator-initiated trial was financially supported by
the Swiss National Science Foundation (SNF grants 32003B-
120020 and 320030-138439) and Ethicon Endo Surgery USA.
The authors declare no conflicts of interest. The sponsors had no
role in study design, data accrual, data analysis, or manuscript
preparation. The first author wrote the first draft of the manuscript.
All the authors had full and independent access to all the data and
vouch for the integrity and the accuracy of the analysis and its
adherence to the protocol.
Study Outcomes
The primary end point of the study was weight loss defined by
excessive BMI loss (EBMIL) over a period of 5 years. Secondary end
points were the rate of perioperative and long-term morbidity and
mortality, the remission rates of the associated comorbidities, the
change in quality of life, and metabolic effects in subgroup
analyses.14–18 This report provides the 3-year interim outcomes in
the study patients, including measures of weight loss, course
of comorbidities (remission, improved, unchanged, worsened)
Improved (%) Unchanged (%) Worsened (%)
34.8 0.0 0.0
25.0 3.8 0.0
35.4 16.7 4.1
26.1 2.2 0.0
35.0 0.0 5.0
23.0 0.0 0.0
9.8 0.0 0.0
17.8 0.0 0.0
37.2 14.0 4.6
47.5 7.5 2.5
5.0 14.6 19.4
14.3 6.1 2.0
9.1 0.0 9.1
0.0 0.0 0.0
40.0 33.3 0.0
22.2 44.4 0.0
significant differences seen were in remission of dyslipidemia (

) and worsening of
: preoperative prevalence.
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ing micronutrient deficiencies), and quality of life (as evaluated with
the use of the Gastrointestinal Quality of Life Index (¼ GIQLI) and
the BAROS Quality of Life Score).19,20
Definition of Comorbidities
Preoperative Comorbidities
Hypertension: systolic blood pressure 140 mm Hg or more
and/or diastolic blood pressure 90 mm Hg or antihypertensive drug
therapy; diabetes mellitus type 2 (T2DM): fasting plasma glucose
126 mg/dL or 2-hour plasma glucose 200 mg/dL during oral
glucose tolerance test or antidiabetic drug with or without insulin
therapy; dyslipidemia: fasting high-density lipoprotein <40 mg/dL
for men, <50 mg/dL for women, and/or triglycerides >150 mg/dL
and/or low-density lipoprotein >100 mg/dL or the use of statins;
obstructive sleep apnea syndrome: in all patients, the Epworth
Sleepiness questionnaire was applied; in case the score was
>10 and/or signs of obstructive sleep apnea (eg, snoring, pauses
in breathing) were present, pulse oximetry was performed followed
by polysomnography21; Gastro-esophageal reflux (GERD): all
patients received upper GI series, gastroscopy and manometry.
FIGURE 1. Flow diagram (study overview).
468 | www.annalsofsurgery.comGERD defined as: need for proton pump inhibitor agents (PPI)
and/or esophagitis diagnosed on endoscopy and/or abnormal man-
ometry. Patients with severe GERD (preexisting symptomatic GERD
despite PPI medication) were excluded from the study; arthralgia:
clinical and radiological findings; depression: all patients were seen
by a psychiatrist. Depression as diagnosed by the psychiatrist and/or
intake of antidepressants; hyperuricemia: plasma uric acid concen-
trations >476 mmol/L and/or intake of antihyperuricemic drugs
(Table 1).
Postoperative Comorbidities
In hypertension, dyslipidemia, GERD, OSAS, arthralgia,
depression, and hyperuricemia the following definitions were
applied: remission: defined as lack of symptoms and discontinuation
of treatment; improved: reduction in treatment; unchanged: no
difference to baseline; worsened: new treatment necessary or treat-
ment intensified; new onset: disease diagnosed postoperatively. The
remission of T2DM was defined according to the American Diabetes
Association criteria for complete remission with HbA1c <42 mmol/
mol (6.0%), fasting glucose <5.6 mmol/L (100 mg/dL), and at least
1 year’s duration in the absence of active pharmacologic therapy or
22ongoing procedures (Table 2).
 2016 The Author(s). Published by Wolters Kluwer Health, Inc.
cantly after both procedures with no statistically significant
FIGURE 2. Weight loss: BMI and EBMIL, BMI significantly
decreased for both treatments from baseline at all 3 years
postop (P <0.001). In both treatment groups, BMI increased
slightly but significantly from year 2 to year 3 (P ¼ 0.01). There
were no statistically significant differences between the 2
groups. EBMIL was also similar between LSG and LRYGB at
each time point (at 1 year: 7222% in LSG group vs.
7522% in LRYGB group, P ¼ 0.14; at 2 years: 7530%
vs. 7830%, P¼ 0.51; and at 3 years: 7124% vs. 7323%,
P ¼ 0.29 respectively). Scatter plot: red dots: LSG, blue
Annals of Surgery  Volume 265, Number 3, March 2017 LSG Vs. LRYGB Similar 3-Year OutcomeCholecystolithiasis: patients with preexisting gallstones
received concomitant cholecystectomy. Patients without gallstones
routinely received gallstone prophylaxis with ursodeoxycholic acid
during the first 6 months after surgery.
Operation Techniques
In all patients standardized operation techniques were used.
LSG: for calibration of the gastric tube, a 35-Fr bougie along
the lesser curvature was used and the longitudinal resection of
the stomach was done from approximately 3 to 6 cm orally of the
pylorus to the angle of His. The staple line was oversewn with an
absorbable running suture. Hiatal hernias were explored and
repaired with posterior closure of the crura. LRYGB was performed
with a 50-cm long biliopancreatic limb and a 150-cm antecolic
Roux-limb using either a linear stapled or circular stapled (25-mm)
gastrojejunostomy. To guarantee standardization of the 2 pro-
cedures, prior to inclusion of the first patient, all participating
surgeons were invited to an instruction session by the principal
investigator (RP), where the standardized operation techniques
were demonstrated.
Statistical Analysis
To detect a 10% difference in EBMIL between the 2 pro-
cedures, we calculated a study size of 200 patients to reach 94%
power at 5 years. Data analysis was performed using IBM SPSS for
Windows (version 21; IBM, Armonk, NY). Values are reported as
meansSD. Descriptive statistics were used for demographic vari-
ables such as age, weight, and BMI. Analysis was performed on the
intention-to-treat population using the last observation carry forward
imputational approach to deal with missing follow-up values. Stu-
dent t, chi-square, and Fisher exact 2-sided tests were used where
appropriate. Longitudinal comparisons were done using repeated
measure analysis of variance with Sˇidak multicomparison test.
Treatment group was used as a covariate. A P value of less than
0.05 was considered statistically significant.
RESULTS
Of approximately 4000 patients, who underwent primary bari-
atric surgery in the 4 study centers, 225 agreed to participate in this
randomized, controlled trial. Of the 225 patients who underwent
randomization from January 2007 through November 2011, a total
of 8 patients were excluded after randomization; 1 patient crossed over
from the LRYGB to the LSG group because of unexpected dense
adhesions of the jejunum, which were detected intraoperatively, and 7
patients were operated on after November 2011 when the recruitment
phase was closed. This resulted in a total of 217 patients who were
included in the study and assigned to either the LSG or LRYGB group.
After 3 years, 6 patients were lost to follow-up: in the LRYGB group 1
patient died within 30 days, another died due to lymphoma 2.5 years
postop, 2 patients moved away; in the LSG group, 2 patients moved
away. The remaining 211 patients (97.2%) were evaluated in the 3-year
assessment of efficacy and safety (Fig. 1). The baseline characteristics
of the 217 patients were reported previously and are described in Table
1.13 There were no significant differences between the study groups at
baseline. Analysis was performed on the intention-to-treat population.
Therefore, the 2 patients in the LSG group who were converted to
LRYGB remained in the LSG group for analysis.
Primary End Point
Body weight and BMI significantly decreased for both
treatments from baseline compared with 1, 2, and 3 years postop
(P <0.001). In the LRYGB group, weight increased slightly but
significantly from year 2 to year 3 (P ¼ 0.01) and in both treatment
groups, BMI increased slightly but significantly from year 2 to year 3
 2016 The Author(s). Published by Wolters Kluwer Health, Inc.(P ¼ 0.01). There were no significant differences between the
treatments in BMI loss or weight loss. Reduction in body weight
expressed as EBMIL was also similar between LSG and LRYGB
at each time point (at 1 year: 72.3 21.9% vs. 76.6 20.9%,
P ¼ 0.139; at 2 years: 74.7 29.8% vs. 77.7 30%, P ¼ 0.513;
and at 3 years: 70.9 23.8% vs. 73.8 23.3%, P ¼ 0.316) (Fig. 2).
The percentage of patients with EBMIL>50% was 80% in the
LSGand85%intheLRYGBgroup,andEBMIL>75%wasobservedin
46%ofLSGpatientsand50%ofpatientsintheLRYGBgroup.Therewas
no statistically significant difference between the 2 treatments.
Comorbidities
After 3 years, comorbidities (glycemic control, hypertension,
OSAS, arthralgia, depression, and hyperuricemia) improved signifi-triangles: LRYGB.
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pidemia were better treated with LRYGB (Tables 2 and 3).
Glycemic Control
At baseline, 24% of LSG and 26% of LRYGB patients
had type 2 diabetes, of which 23% in the LSG group and 21% in
the LRYGB group were insulin-dependent, respectively. After 3
years, complete remission was seen in 60% of LSG patients and
in 77% of LRYGB patients (P ¼ 0.23). Marked amelioration of
glycemic control was seen after 3 years: HbA1c decreased signifi-
cantly for both treatments and median levels of fasting plasma
glucose were significantly lower from baseline to year 3. There
was no overall significant difference between the treatment groups
(Tables 2 and 3).
Dyslipidemia
At baseline, 67% of the LSG patients and 51% of the LRYGB
patients suffered from dyslipidemia. After 3 years, complete remis-
sion rate was 44% in LSG and 72% in LRYGB (P ¼ 0.008).
Significant improvement was seen in both groups; however, the rate
of decline of total cholesterol and LDL was significantly higher in the
LRYGB group compared with LSG, adjusted for baseline values.
Triglycerides decreased in both treatment groups from base-
line to year 3 (P <0.001). The values of TG were not significantly
TABLE 3. Secondary Endpoints
A: Diabetic Patients (LSG: n ¼ 26; LRYGB: n ¼ 28)
End Point Group Baseline Year 1 Year
Fasting Glucose (mmol/L) LSG 7.7 0.75 5.8 0.38 6.0
LRYGB 6.7 0.47 5.4 0.23 5.6
HbA1C LSG 7.62 0.38 6.12 0.21 6.51
LRYGB 7.25 0.37 5.76 0.15 5.97
B: Patients With Preexisting Dyslipidemia (LSG: n ¼ 72; LRYGB: n ¼ 56)
End Point Group Baseline 3 Yrs
Total Cholesterol LSG 5.67 0.15 5.11 0.93
LRYGB 5.42 0.18 4.65 0.14
HDL LSG 1.13 0.04 1.55 0.06
LRYGB 1.13 0.04 1.6 0.06
Chol/HDL ratio LSG 5.39 0.26 3.9 0.34
LRYGB 4.92 0.19 3.01 0.09
LDL LSG 3.45 0.14 3.16 0.12
LRYGB 3.41 0.17 2.78 0.1
TG LSG 2.22 0.16 1.35 0.11
LRYGB 2.07 0.16 1.18 0.10
C: Quality of Life, All Patients (LSG: n ¼ 107; LRYGB: n ¼ 110)
End Point (MeanSD) Group Baseline 1 Yr
GIQLI Score LSG 100.0 20.6 126.3 13.4
LRYGB 99.3 17.5 128.5 9.3
BAROS QoL Score LSG 0.1 1.2 1.9 0.8
LRYGB 0.2 1.3 1.9 0.6
A: Improvement of glycemic control in diabetic patients. At 3 years there was no signific
significant improvements of lipid profiles in both groups. Rate of decline for LDL and total
baseline values. Values are expressed as meanSD.
C: Quality of life measured by GIQLI score and BAROS QoL score. GIQLI score for hea
preoperatively and remained high. There was no difference between the 2 groups. Values a
470 | www.annalsofsurgery.comdifferent between the treatments, neither was the rate of decline when
adjusted for baseline values (Tables 2 and 3).
Gastroesophageal Reflux Disease
At baseline, 44% had GERD in the LSG group, and 46% in the
LRYGB group. After 3 years, in the LSG group, 61% experienced
remission, 5% symptoms improved; in 15% symptoms were
unchanged and in 20% worsened.
In the LRYGB group, 78% experienced remission, in 14%
symptoms improved; in 6% symptoms were unchanged and in 2%
worsened. At 3 years, the difference in remission rate between the
groups did not reach significance (P ¼ 0.09), but worsening of
symptoms was more often seen in the LSG group (P¼ 0.01, Table 2).
In addition, of the 66 LSG patients with no GERD at baseline, 18%
developed de novo GERD symptoms whereas this was only seen in
2% of LRYGB patients (P ¼ 0.002).
Quality of Life
The mean GIQLI score (GIQLI¼Gastrointestinal Quality
of Life Index) and BAROS quality of life (QoL) (BAROS¼Bari-
Bariatric Analysis and Reporting Outcome System) increased
significantly in both groups after 1 year compared with baseline.
Assessment of GIQLI score and BAROS QoL at 2 and 3 years
demonstrates that patients experience a significant and sustainable
improvement in quality of life compared with baseline with a
3
P Values
Baseline Vs. Year 1 Baseline Vs. Year 3 Between Groups
0.32 0.115 0.211 0.141
0.22 0.040 0.080
0.31 0.005 0.035 0.129
0.16 <0.001 0.001
P Values Baseline
to Year 3
Between
Groups
Rate of Decline
Between Groups
0.001 0.053 0.033
<0.001
<0.001 0.661 0.423
<0.001
<0.001 0.031 0.070
<0.001
0.043 0.202 0.018
<0.001
<0.001 0.327 0.368
<0.001
2 Yrs 3 Yrs
Baseline Vs.
Year 1
Between
Groups
124.5 16.9 117.4 22.6 0.001 0.366
126.5 14.8 121.2 13.9 0.003
1.9 0.9 1.7 0.8 <0.001 0.535
2.0 0.8 1.7 0.9 <0.001
ant difference in fasting glucose or HbA1c between LSG and LRYGB. B: Dyslipidemia:
cholesterol was significantly higher in LRYGB group compared with LSG, adjusted for
lthy individuals ¼ 121. After 1 year, quality-of-life scores were significantly higher than
re expressed as meanSD.
 2016 The Author(s). Published by Wolters Kluwer Health, Inc.
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statistically significant difference between the 2 groups at any
time point (Table 3).
Adverse Events
Additional surgical interventions were required in 9 patients in
the LSG group and in 16 patients in the LRYGB group from
postoperative day 30 until the 3-year follow-up (8% vs. 15%, P ¼
0.15). In the LSG group, there were 2 patients converted to bypass
due to severe GERD, 4 patients needed cholecystectomy due to
newly developed, symptomatic gallstones, 2 patients suffered from
insufficient weight loss (1 conversion into laparoscopic bilio-pan-
creatic diversion duodenal switch and 1 to LRYGB), and 1 patient
had an umbilical hernia repair. In the LRYGB group 6 patients
required cholecystectomy, 2 had a small bowel obstruction, 3 patients
were treated for internal hernia by laparoscopy, in 1 patient a Fobi-
ring was inserted to increase weight loss by adding restriction.23,24 In
addition, 1 patient had an umbilical hernia repair, 1 patient under-
went laparoscopy for gastroduodenoscopy, in 1 patient abdominal
lavage had to be carried out due to an infectious early complication,
and 1 patient had a resection of a Meckel diverticulum. In the 3-year
follow-up there was no patient in either group with extreme weight
loss (BMI 18 kg/m2) or hypoalbuminemia and no life-threatening
complications or deaths associated with the intervention occurred.
No statistically significant difference in complications treated con-
servatively such as peptic ulcer, stricture, kidney stones, and micro-
nutrient deficiencies between the 2 groups was found (Table 4).
DISCUSSION
The present study explored whether LSG compared with the
current gold standard in bariatric surgery, laparoscopic gastric bypass
(LRYGB) is equally effective in: 1) weight loss, 2) remission of
TABLE 4. Complications (1 Month to 3 Yrs)
Complication
LSG
(n ¼
Conservative treatment
General complications
Total 9
Peptic ulcer 0
Stricture 0
Kidney stones 2
Other 7
Deficiencies
Total: patients with 1 micronutrient deficiency 39
Vit. D 34
Vit. B12 39
Iron 24
Zink 16
Folate 10
Protein 0
Operative treatment
Total 9
Conversion to LRYGB for GERD 2
Choleystectomy for newly acquired gallstones 4
Revision for small bowel obstruction 0
Internal hernia 0
Insufficient weight loss 2
Other (umbilical hernia, Meckel diverticulum,
gastroduodenoscopy, abdominal lavage, etc.)
1
The reoperation rate was slightly higher in the LRYGB group. There was no statistical
 2016 The Author(s). Published by Wolters Kluwer Health, Inc.comorbidities, 3) increase in quality of life, and 4) whether the 2
procedures are equally safe in long-term outcome.
Both procedures were highly effective in terms of weight loss
with an excessive BMI loss at 3 years of 70.9% in the LSG group and
73.8% in the LRYGB group. The weight loss nadir was between 1
and 2 years postop with a discrete weight regain thereafter. LRYGB
showed a nonsignificant better weight loss at each time point that is
in line with most previously published series and meta-analyses.7–
11,25,26
Differences in the amelioration of glycemic control in patients
with T2DM between the 2 procedures are still controversially dis-
cussed. According to some study groups, LRYGB shows superiority to
LSG in T2DM remission.27 Other groups found the opposite and even
describe superiority of LSG in diabetes remission.28 However, only a
few, prospective randomized-controlled studies have compared out-
come of LRYGB versus LSG, unfortunately with either only a small
number of patients or short follow-up.7–11 The STAMPEDE trial is
doubtless the most important trial so far, comparing best medical
treatment versus LSG and LRYGB with 50 diabetic patients in each
arm over a period of 3 years.9 Regarding HbA1c<6.0% the 2 surgical
arms were clearly superior to the conservative arm, but no statistically
significant difference between the 2 surgical groups was found. In
contrast, other endpoints (HbA1C <7% without medications, insulin
dependency, and number of medications used) showed superiority of
LRYGB over LSG.9 In our trial, no statistically significant difference
in resolution of T2DM and amelioration of glycemic control could be
shown, which is in line with a recently published trial by Yang et al.12
However, it should be noted that the SM-BOSS trial is not powered
enough for this end-point.
Remission rates of other comorbidities showed equal effects,
with the exception of GERD and dyslipidemia. Patients with severe,
preexisting GERD (symptomatic GERD despite PPI medication) and
107)
LRYGB
(n ¼ 110)
P Values LSG
Vs. LRYGB
11 0.67
1
1
1
8
45 0.59
26
45
29
20
5
1
16 0.15
NA
6
2
3
1
4
ly significant difference between the 2 groups.
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not included in the study, as in this case a LRYGB is clearly superior
to LSG. Nevertheless, many morbidly obese suffer from intermittent
reflux, which can exacerbate after LSG. Preexisting reflux was more
efficiently treated with LRYGB and significantly more patients
suffered from new onset reflux in the LSG group. In most cases,
GERD could be treated conservatively with PPIs. However, in 2
patients, pharmaceutical treatment was insufficient and LSG had to
be converted to LRYGB to treat refractory severe GERD. Dyslipi-
demia improved in both groups; however, decrease in total choles-
terol and LDL was more pronounced in the LRYGB group compared
with LSG and remission rate for dyslipidemia was higher in LRYGB
compared with LSG. Quality of life improved significantly in both
groups after surgery at 1 year compared with baseline, and remained
stable up to 3 years postsurgery. There was no difference observed
between the 2 groups, despite the difference seen in GERD. There
was no statistically significant difference in complications within the
first 3 years postop.
The rate of reoperations in the LRYGB group was slightly
higher, but not statistically significant, which might probably be due
to insufficient power for this secondary endpoint.
In the present study, we found no difference in vitamin
deficiencies between the 2 groups, which is in contradiction to a
previously conducted retrospective analysis, where we found a lower
deficiency rate following LSG.29 Both groups had a rather high rate
of deficiencies despite regular vitamin supplementation in all
patients. The very high follow-up rate (97%) with regular laboratory
investigations may explain the high prevalence. No severe malnu-
trition was observed. These results demonstrate the need for life-long
vitamin supplementation and monitoring of deficiencies following
LSG and LRYGB.
As a limitation of this study we would like to mention that the
design of the study was powered at 5 years for the primary endpoint
(weight loss) and is underpowered for T2DM remission (with only 26
vs. 28 diabetic patients in each treatment arm) and reoperation rate
(with 9 vs. 16 reoperations in each arm). The results discussed are
part of an interim analysis. Up-to-date SM-BOSS is the largest
randomized controlled trial comparing LSG to LRYGB with a nearly
complete follow-up rate at 3 years.
In conclusion, in this trial, LSG and LRYGB were equally
efficient regarding weight loss, quality of life, and complications up to
3 years postsurgery. Improvement of comorbidities was similar except
for GERD and dyslipidemia that appear to be more successfully treated
by LRYGB. In our opinion, patients with preexisting symptomatic
gastro-esophageal reflux disease (GERD) despite medication, or
patients successfully treated with PPIs but refusing long-term acid-
inhibitory medication, large hiatal hernia (para-esophageal hernia or
axial hernia >4 cm), and severe gastroesophageal motility disorders
are better treated with a LRYGB procedure. Concerning dyslipidemia,
no conclusions can be drawn at this moment. However, LRYGB might
be a better choice in patients with additional cardiovascular risk factors
such as history of cardio-vascular event, smoking, arterial hyperten-
sion, or inherited predisposition for cardio-vascular disease.
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